Skip to content

DERMAROLLER WITH PLATELET RICH PLASMA IN ACNE SCARS

A COMPARATIVE STUDY OF MICRONEEDLING ALONE VERSUS ALONG WITH PLATELET RICH PLASMA IN ACNE SCARS

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/11/016264
Enrollment
40
Registered
2018-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L905- Scar conditions and fibrosis of skin Health Condition 2: L905- Scar conditions and fibrosis of skin

Interventions

Intervention1: Microneedling with platelet rich plasma: Microneedling with platelet rich plasma on one side of face(on acne scars) Control Intervention1: Microneedling: Microneedling alone on other si

Sponsors

NOT SPONSORED
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with facial atrophic acne scars. 2.Patients >18 years old and

Exclusion criteria

Exclusion criteria: 1.Patients who have undergone any skin resurfacing procedures within the preceding 1 year. 2.Patients taking systemic retinoids or immunosuppressives drugs during or within 6 months before the study. 3.Patients with history of coagulation defects or bleeding diathesis. 4.Patients with history or tendency to develop of keloid scars. 5.Patients with active acne lesions.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of microneedling alone versus along with Platelet rich plasma in management of post acne scars. Timepoint: To compare the efficacy of microneedling alone versus along with Platelet rich plasma in management of post acne scars.

Secondary

MeasureTime frame
1. To study the clinical profile of acne scars Timepoint: 6 months

Countries

India

Contacts

Public ContactDr Krishna Deb Barman

Maulana Azad Medical College Delhi

kdebbarman@yahoo.com9968604371

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026